Latest News
Tesla is expected to begin production of Optimus Gen 3 later this year.
Via The Motley Fool · February 24, 2026

Macerich (MAC) Q4 2025 Earnings Call Transcript
Via The Motley Fool · February 24, 2026
Navitas stock has jumped 188% over the past year, but is it a better buy?
Via The Motley Fool · February 24, 2026
Via Talk Markets · February 24, 2026
Via Talk Markets · February 24, 2026
Via Talk Markets · February 24, 2026
Even a modest investment in Nvidia stock a decade ago would have turned into a staggering amount of money.
Via The Motley Fool · February 23, 2026

This value-focused home furnishings retailer attracted a recent insider buy, according to SEC filings.
Via The Motley Fool · February 23, 2026
Via Talk Markets · February 24, 2026
On Monday, Wedbush maintained its $19 price target on Ardelyx shares, implying a 230% upside from current levels.
Via Stocktwits · February 24, 2026
Via Talk Markets · February 24, 2026
Via Talk Markets · February 24, 2026
Netflix is still growing at a rapid clip. But as competition intensifies, how sustainable is its growth story?
Via The Motley Fool · February 23, 2026
Via Talk Markets · February 24, 2026
The power needs of AI have created an opportunity for companies pioneering SMR technology.
Via The Motley Fool · February 23, 2026
Jeff Bezos praised Ryan Gosling's performance in Project Hail Mary as Amazon rolls out Prime-exclusive early screenings ahead of the film's March 20, 2026 release, while the company's shares slipped despite after-hours gains.
Via Benzinga · February 24, 2026
Via Talk Markets · February 24, 2026
Via Talk Markets · February 23, 2026
Via Talk Markets · February 24, 2026
Tesla is pushing deeper into Robotaxi and AI, but exciting initiatives don't automatically make the stock a buy.
Via The Motley Fool · February 23, 2026

Expense ratios, volatility, and fund structure set these two precious metals ETFs apart in ways that matter for portfolio risk.
Via The Motley Fool · February 23, 2026
ImmunityBio outlined a three-year plan to position Anktiva as a backbone immunotherapy, advancing more than 30 trials across 10 tumor types.
Via Stocktwits · February 23, 2026
Palantir has delivered incredible results recently, so why is the stock down?
Via The Motley Fool · February 23, 2026